Minerva Neurosciences (NASDAQ:NERV) Announces Quarterly Earnings Results, Misses Estimates By $1.46 EPS

Minerva Neurosciences (NASDAQ:NERV) announced its quarterly earnings data on Friday. The biopharmaceutical company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($1.46), Zacks reports.

Minerva Neurosciences Stock Performance

Minerva Neurosciences stock traded up $0.12 during mid-day trading on Friday, hitting $2.42. The company’s stock had a trading volume of 238,027 shares, compared to its average volume of 175,064. The stock has a market cap of $115.56 million, a PE ratio of -0.08 and a beta of 0.09. The company has a 50 day moving average of $3.22 and a 200-day moving average of $4.83. Minerva Neurosciences has a one year low of $1.96 and a one year high of $8.80.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Zacks Research raised shares of Minerva Neurosciences from a “strong sell” rating to a “hold” rating in a report on Friday, October 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Minerva Neurosciences in a research report on Monday, September 21st. Jefferies Financial Group raised Minerva Neurosciences from a “hold” rating to a “mixed” rating and increased their target price for the stock from $7.50 to $10.00 in a research note on Friday, August 14th. Finally, Wall Street Zen cut shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Minerva Neurosciences presently has an average rating of “Hold” and an average price target of $10.33.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s research has centered on conditions with significant unmet medical needs, including schizophrenia, depression and other psychiatric or neurological diseases.

Minerva’s lead product candidate has been roluperidone, an investigational therapy designed to address the negative symptoms of schizophrenia, such as social withdrawal, reduced motivation and diminished emotional expression.